Actively Recruiting
Use Misoprostol to Optimize Prevention of Cervical Cancer
Led by University of Alabama at Birmingham · Updated on 2025-10-01
420
Participants Needed
1
Research Sites
140 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
C
Cameroon Baptist Convention Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
CONDITIONS
Official Title
Use Misoprostol to Optimize Prevention of Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Type 3 transformation zone confirmed on exam prior to randomization
- Age 25 years or older
You will not qualify if you...
- Having Type 1 or 2 transformation zone prior to randomization
- Currently pregnant
- History of hysterectomy
- Any cancerous lesions
- Active cervicitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé
Yaoundé, Center Region, Cameroon, 2034
Actively Recruiting
Research Team
W
Warner K Huh, MD
CONTACT
S
Simon M Manga, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here